Elsevier MDL collaborates with NIH to catalog biological properties of small molecules

Elsevier MDL contributes structures from xPharm® database to PubChem

San Leandro, CA - December 19, 2005 - Elsevier MDL today announced an agreement with the National Institute of Health (NIH) to contribute to the NIH effort to catalog information on the biological properties of small molecules in its freely available PubChem database. Elsevier MDL will enrich the growing PubChem resource for the scientific community by furnishing chemical structures from Elsevier’s xPharm® database, giving scientists with an xPharm license the ability to move from biological data in PubChem to more focused pharmacology data in xPharm that is essential to drug research.

“Elsevier MDL is pleased to collaborate with the NIH to give commercial, academic and governmental researchers broader access to vital research information,” said Elsevier MDL CEO Lars Barfod. “xPharm provides its licensed customers an ideal set of compounds for medicinal chemists, biologists, pharmacologists and other researchers to determine starting points for pharmacological research. The addition of xPharm chemical structures makes PubChem an even more valuable resource, allowing researchers who have licensed xPharm to link from chemistry and biology data in PubChem to authoritative pharmacology data and associated target and disorder data.”

“We're pleased to have the support of Elsevier MDL, and welcome these biologically very interesting new links from the xPharm database in PubChem,” said Steve Bryant, Director, PubChem, National Institute of Health. “It is our intent to make PubChem as comprehensive as possible and this type of collaborative effort is invaluable.”

xPharm is a comprehensive and authoritative collection of pharmacological data, with chemical agents representing the best examples of pharmacological activity. The interlinked biological and pharmacological disorder data combines to provide researchers with more detailed pharmacology data in a single online source. xPharm is available via the online DiscoveryGate® platform for accessing integrated scientific content from databases, journal articles, patent publications and reference works. xPharm structures in PubChem will be linked directly to their corresponding pharmacological data on DiscoveryGate.

The contribution of xPharm structures marks the first step in Elsevier MDL’s efforts to support the NIH Roadmap initiative. Elsevier MDL and NIH plan additional collaboration related to the PubChem database in the future.

###

About NIH
The National Institutes of Health (NIH) - The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. The PubChem database, a component of National Institute of Health's (NIH) Molecular Libraries Roadmap Initiative, is a comprehensive database of chemical structures and their biological activities being developed by the National Center for Biotechnology Information (NCBI) at NIH. For more information about NIH and its programs, visit http://www.nih.gov.

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services.

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information visit www.reedelsevier.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

CONTACT:
Dr. Phil McHale
Elsevier MDL
VP, Market and Corporate Communications
Phone: (510) 357-2222 ext. 3541
p.mchale@mdl.com

###

MDL and DiscoveryGate are registered trademarks of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States. All rights reserved. xPharm is a registered trademark of Elsevier Inc., in the United States and other countries. All other trademarks mentioned in this document are the property of their respective owners.